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Background:  Chronic kidney disease (CKD) is associated with poor outcomes after percutaneous coronary intervention (PCI). The aim of 
our study was to compare biodegradable polymer biolimus-eluting stent (BES) and durable biocompatible polymer everolimus-eluting stent 
(EES) used during PCI in patients with CKD.
methods: From May 2011 to April 2012, we enrolled 1327 consecutive patients with the NOBORI BES, 503 (37.9%) of whom had CKD 
(estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2). As a historical control group, a total of 1140 consecutive patients with 
the XIENCE/PROMUS EES between February 2010 and August 2012 were enrolled, 477 (41.8%) of whom had CKD. Patients with 
hemodialysis were excluded. The primary endpoint was the rate of major adverse cardiovascular events (MACE), defined as a composite 
of cardiac death, myocardial infarction, definite stent thrombosis, clinically driven target lesion revascularization (TLR) at 2-year.
results: Baseline characteristics were similar between the BES and EES groups. Patients with diabetes mellitus and multi vessel coronary 
disease were similar between the 2 groups (43.3% vs. 48.8%, P=0.31; 32.2% vs. 35.0%, P=0.31, respectively). At 2-year, the incidence of 
MACE was not significantly different between the BES and EES group (8.8% vs. 11.2%, P=0.22). Cumulative incidence of cardiac death, 
myocardial infarction, definite stent thrombosis, and clinically driven TLR were not significantly different between the 2 groups (2.8% vs. 
3.2%, P=0.75, 1.0% vs. 0.7%, P=0.52, 0.4% vs. 0.3%, P=0.59; 5.0% vs. 6.8%, P=0.31, respectively). At Cox regression analysis, predictor 
of 1-year MACE were left ventricular ejection fraction <40%, prior coronary intervention, eGFR <30 mL/min/1.73 m2, and anemia.
Conclusion:  2-year clinical outcome after biodegradable polymer BES implantation in patients with CKD was not significantly different 
from that after durable polymer EES. This study suggests that both BES- and EES-use are acceptable in CKD patients.
